CHAMPION

CARE CORP.

Improving the lives of chronic pain patients.

Pursuing a Public Listing and

Financing to Provide Chronic

Pain Treatments to 100 Million

Patients in Europe.

Champion Care Corp.

The Chronic Pain Market in Europe

The overall market is large and growing.

• Globally, 1.5 billion people are affected by chronic pain, making it the number one

reason patients seek medical care.

• In Europe, nearly 100 million patients suffer from moderate to severe pain.

• The direct cost of treating these patients is

estimated to be €30 billion, annually.

• The number of patients suffering from chronic pain is expected to increase with

aging populations.

Abuse of prescription medications for the treatment of

chronic pain has led to restrictions on their use and a

search for alternative, less dangerous methods for the

treatment and management of chronic pain.

“Urgent action is needed across Europe to prioritize

chronic pain as a healthcare problem” – Source: Pain

Alliance Europe, 2014.

Champion has developed a proprietary pain

treatment protocol (the “Protocol”) which is highly effective, economical, provides enduring relief

from pain and reduces the demand for prescription medications.

Champion Care Corp.

The Cause of Chronic PainTissue damage leads to inflammation which causes pain.

Prolonged pain causes a reduction in endorphins and other neurotransmitters that relievepain. Pain then increases and persists unless neurotransmitter levels can be restored.

Tissue damage Inflammation

Pain + TimeReduced neurotransmitters

Increased Pain

Champion Care Corp.

Medications vs. the Protocol for Treating Chronic Pain

Nerves

Brain perceives pain Signals to Brain

Tissue damage causes pain initiators to send signals through nerves to the brain.

Damaged tissue Pain Initiators

Aspirin, & ibuprofen

block formation of

pain initiators. Novocain

blocks signals

to the brain.NEUROTRANSMITTERS,

morphine & oxycodone decrease

perception of pain.

The Protocol alleviates pain by boosting NEUROTRANSMITTER levels.

Champion Care Corp.

The Protocol is a personalized treatment program designed to restore neurotransmitter levels.

On-going counseling, and regular checkups to review progress, amend the treatment program and promote adherence to the Protocol.

Topical pain medication.

Regular activity regimens and the use of Cranial Electrotherapy Stimulation to promote restorative sleep.

Dietary changes, nutritional supplements and light exercise to restore neurotransmitter levels and reduce inflammation.

Relaxation training to reduce stress.

Education about chronic pain and on-going support to establish and maintain beneficial behavioural changes.

Testing to provide accurate diagnoses, determine candidacy, monitor progress and maintain post-treatment support.

Champion Care Corp.

The Champion Protocol Pilot Study

The Protocol is proven to be effective.

• In Canada and the US, 87 patients with severe chronic pain which had not been resolved by any

previous treatments, took part in a pilot study of the Protocol.

• The patients paid personally for their own treatments with the Protocol and experienced a

significant and lasting relief from pain as shown below.

• Incidences of waking up from pain. 53% fewer times.

• Hours of sleep. 16% more hours.

• Maximum pain level. 39% reduction.

• Average pain level. 61% reduction.

• Energy level. 31% increase.

• Hours per day of no pain. 286% more hours.

Voluntary testimonials from representative patients are provided on the next page and full results are

available on request.

Champion Care Corp.

Testimonials for the Protocol

Our US trial was conducted at Summit Pain Specialists in Ohio, USA. The

voluntary patient testimonials from this trial may be seen at:

• http://www.youtube.com/watch?v=IKsnT-oE1Uk

• http://www.youtube.com/watch?v=nKpnQsijm4E&feature=email

• http://www.youtube.com/watch?v=1Zs2q8zdKlc&feature=email

• http://www.youtube.com/watch?v=6-wXFkaCyAI&feature=email

• http://www.youtube.com/watch?v=5yrq5UWwR_g&feature=email

• http://www.youtube.com/watch?v=R5dI3pYfIS4&feature=email

Champion Care Corp.

Benefits of the Champion Protocol

Reduces pain levels and provides longer periods without pain even when conventional medical interventions have failed.

Satisfies the need of patients who want to decrease their dependence on medications or surgeries.

Decreases risk to patients from side effects of medications or addiction to prescription drugs.

Vastly improves the quality of life for patients through regenerative sleep, mood improvement, increased activity levels and ability to return to normal work habits.

Benefits society at large by reducing the burden of chronic pain patients on the medical system and allowing many people to return to their regular work.

Provides the funding agencies with significant cost savings.

Provides doctors with competitive advantages and additional revenues.

Reduces doctors’ risks of liability or licensing board infractions from over-use of prescription medications.

Satisfies the increasing requirement of licensing boards to reduce the use of opiates and other strong or addictive medications.

Champion Care Corp.

Champion’s Markets

GLOBALLY, 1.5 BILLION PATIENTS SUFFER FROM CHRONIC PAIN

100 MILLION AMERICANS 150 MILLION EUROPEANS

Chronic pain is the #1 reason patients seek medical care

US market for all pain patients is $60 Billion in 2015

EU market for treating moderate to severe pain is

€30 Billion

Champion Care Corp.

Chronic Pain in the USA

• Champion and its principals hold 73,355,000 shares (61%) of CPAI.

• Three of four Directors of CPAI are Directors of Champion.

• A License Agreement provides CPAI with the exclusive use of the Protocol in the US.

• A Services Agreement provides compensation to Champion for services rendered to CPAI.

Champion controls

Champion Pain Care Corporation,

an OTCBB company (“CPAI”).

• The treatment of pain patients in the US is a very fragmented market.

• There are approximately 1,500 private clinics specializing in pain treatments in the US, usually run by only 1 or 2 doctors.

• A representative sample of clinics averaged revenues of US$2.6 Million and EBITDA’s of 24.7%, leading to a US market estimate of nearly $4 Billion.

• Payments for pain treatments are provided by Bureaus of Workers’ Compensation, national and regional health insurers, managed health care companies, Medicare, Medicaid and TriCare.

CPAI is pursuing a roll-up of private pain management

clinics in the US.

Further details are available in the Form 10-K filed by CPAI on EDGAR at:http://www.sec.gov/Archives/edgar/data/1469284/000151116415000237/f10k28apr15final.htm

Champion Care Corp.

Chronic Pain in Europe

150 Million Europeans suffer from Chronic pain with 100 Million of those experiencing moderate to severe pain.

The initial target markets in Germany and the UK consist of 21.5 Million patients with moderate to severe chronic pain.

• 88% have never seen a pain management specialist.

• A large majority report that current treatments and medications are inadequate.

In Germany, there are approximately 50 companies that provide private health insurance (“PKV”) and a government health insurance program (“GKV”).

England, Northern Ireland, Scotland and Wales each have their own systems of publicly funded healthcare and each jurisdiction also has a private healthcare providers.

The following strategy is planned for Europe.

• Initiate a marketing program to introduce the Protocol in Germany and the UK.

• Immediately license the Protocol to hospitals, clinics and physicians to increase the number of doctors helping pain patients who are paying privately.

• Pursue approval for funding for the Protocol from the health insurance providers.

• As approvals are provided, pursue license, joint venture and acquisition agreements.

• Expand into other EU member states.

Champion Care Corp.

Listing and funding plan

Champion is seeking CDN$1.75 Million (€1.17 Million) in funding.

• CDN$250,000 (€167,000) of Initial Funding will be used to:

• Investigate public listing opportunities:

• the CSE via a RTO or IPO.

• On the Frankfurt Stock Exchange as a primary or co-listing.

• Establish a presence in Germany and the UK through:

• Funding meetings.

• Selected marketing of the Protocol.

• Recruitment of advisors.

• Licensing of the Protocol to doctors, clinics and hospitals with private-pay patients.

• Introductory meetings with health insurance providers.

• Identification of licensees, joint venture partners and acquisition prospects.

• An estimated additional CDN$1.5 Million (€1 Million) is needed for:

• Completing the public listings in Canada and Germany.

• Marketing.

• Obtaining approval from health insurance providers.

• Completing licensing, joint venture and acquisition agreements.

• Closing additional funding in Canada and Europe to develop the markets in other EU member states.

Champion Care Corp.

Capital Structure and Proposed TermsCapital Structure and Proposed Terms

Capital Structure

•Champion is a private company incorporated in Ontario, Canada on May 14, 2010.

• Four shareholders hold all of the 2 Million shares which are issued and outstanding.

•Net worth estimated to be $4.7 Million (See next page).

• Three years of audited statements will be prepared on completion of sufficient funding.

Proposed terms

•Convertible debt.

•No fixed term.

• FMV interest.

•Secured with CPAI shares and receivable.

•Principal and interest converted to shares at the RTO or IPO price received by Champion.

Champion Care Corp.

Champion Valuation (CDN$Millions)

ASSETS

• 40,355,000 shares of CPAI at $0.0192 (February 18, 2016) 0.8

• Receivable from CPAI as of June 30, 2015 1.4

• Protocol development costs 3.3

Total assets 5.0

LIABILITIES

• Due to shareholders 0.4

• Notes payable 0.3

Total Liabilities 0.7

NET WORTH 4.3

REVENUES

Champion’s US revenues will come from:

• A License Agreement which provides CPAI with the exclusive use of the Protocol in the US.

• A Services Agreement which provides compensation to Champion for services provided to CPAI.

Champion Care Corp.

Management

Terrance Owen, CEO and Director - BSc, (Honours) Biology, UVic, 1968; MSc, Biology, UNB, 1970; PhD, Zoology, UBC, 1974; MBA , SFU, 1991. Director, CPAI, 2012 – Present; CEO, CPAI, 2013 –2015; President, CEO & Director, Vanc Pharmaceuticals Inc., 2000 – 2013; President & Director, Helix Biotech, 1980 – 2002; President & Director,. Helix BioPharma Corp., 1995 – 1998.

Jack Fishman, President, Director & Co-founder – President & Director, CPAI, 2013 – Present; 5 years developing the Protocol; 22 years in management, sales & marketing including such notable companies as Snap-On-Tools & Honda.

Emil Schiller, COO, Director & Co-founder – Director, CPAI, 2012 – Present; COO, CPAI, 2013 –2015; 5 years developing the Protocol; 22 years of high-level management in finance,

operations and planning.

Champion Care Corp.

Summary

In Europe, nearly 100 million patients suffer from

moderate to severe pain. Nearly 22 Million of these patients reside in Germany and the UK.

Globally, 1.5 billion people are affected by chronic

pain, making it the number one reason patients seek medical care.

Champion’s Protocol is highly effective,

economical, provides enduring relief from pain and reduces the demand for prescription medications.

Champion’s Protocol is highly effective,

economical, provides enduring relief from pain and reduces the demand for prescription medications.

In Europe, nearly 100 million patients suffer from

moderate to severe pain. Nearly 22 Million of these patients reside in Germany and the UK.

Globally, 1.5 billion people are affected by chronic

pain, making it the number one reason patients seek medical care.

Champion’s Protocol is highly effective,

economical, provides enduring relief from pain and reduces the demand for prescription medications.

Champion wishes to expand it’s business into

Europe, starting with private pay patients in Germany and the UK.

Champion wishes to expand it’s business into

Europe, starting with private pay patients in Germany and the UK.

Champion’s assets are the Protocol controlling

equity in CPAI, a receivable from CPAI and License and Services Agreements with CPAI.

Champion’s assets are the Protocol controlling

equity in CPAI, a receivable from CPAI and License and Services Agreements with CPAI.

Immediate recruiting of advisors, licensing of the

Protocol to hospitals, clinics and doctors and pursuing payment from insurers is required.

Immediate recruiting of advisors, licensing of the

Protocol to hospitals, clinics and doctors and pursuing payment from insurers is required.

Funding of CDN$250,000 (~€170,000) as

convertible debt is required to initiate these actions and to realize revenues in Europe.

Funding of CDN$250,000 (~€170,000) as

convertible debt is required to initiate these actions and to realize revenues in Europe.

Champion wishes to immediately pursue a

Canadian Stock Exchange listing and funding with a co-listing on the Frankfurt Stock Exchange.

Champion wishes to immediately pursue a

Canadian Stock Exchange listing and funding with a co-listing on the Frankfurt Stock Exchange.

Champion Care Corp.635 Fourth Line, Unit 1

Oakville, ON, Canada

L6L 5B0

Contact:Terrance Owen, PhD, MBA, CEO

owen.terrance@gmail.com

1-604-862-3439